de Verneuil Vanina 4

What Happened
Vanina de Verneuil, EVP, General Counsel and Corporate Secretary of Vir Biotechnology (VIR), reported sales of company stock on Feb 24–25, 2026. She disposed of 3,117 shares at $9.53 each (proceeds $29,713) on Feb 24 and 13,700 shares at $9.82 each (proceeds $134,534) on Feb 25, for total proceeds of approximately $164,247. These were sales (not purchases) and therefore do not represent a bullish insider buy signal.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 3,117 shares sold at $9.53, proceeds $29,713.
  • 2026-02-25: 13,700 shares sold at $9.82, proceeds $134,534.
• Combined shares sold: 16,817; combined proceeds: ~$164,247.
• Footnotes:
  • The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2025 (F2).
  • One footnote notes the sales were automatic/mandatory to satisfy the issuer’s tax withholding obligations in connection with RSU vesting (F1); the trades were not discretionary.
• Filing: Form 4 filed 2026-02-26 for transactions on 2026-02-24 and 2026-02-25 (filed promptly based on the reported dates).
• Shares owned after the transactions: not provided in the summary information supplied.

Context
These transactions were routine sales executed under a pre-established Rule 10b5-1 plan and to cover tax withholding on vested restricted stock units. Such trades are generally administrative and do not necessarily reflect the insider’s current view on the company’s prospects. For retail investors, purchases by insiders are often more informative about sentiment than routine sales made for tax or diversification reasons.